Driven by the potential to confer sustained therapeutic effects and thereby facilitate prolonged periods of remission, TIL-based therapies have received significant financial support, and promising leads are poised to soon achieve blockbuster status
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
- A detailed assessment of the current market landscape of drug developers engaged in the development of TIL-based therapies.
- An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions in this field, and a schematic world map representation engaged in the development of TIL-based therapies.
- Detailed profiles of therapies being evaluated in clinical stages (phase I/II or above).
- An overview of key therapeutic areas that are being targeted by TIL-based therapies. It also includes an assessment of the opportunity across oncological disease indications.
- An analysis of the partnerships that have been established in the recent past.
- An analysis of investments that have been made into companies which have proprietary TIL-based products / technologies.
- A case study on manufacturing of cell therapy products, highlighting the key challenges associated with the production of such therapies.
- An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.
- A review of the key promotional strategies that have been adopted by developers of marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.
- A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
- Target Indication
- Acute Lymphoblastic Leukemia
- Key Players
- Key Geographical Regions
- North America
- Asia Pacific
The research includes brief profiles, featuring an overview of the company, its financial information (if available), details related to its product(s), highlighting type of therapy and current development status, technology portfolio (if available), recent developments and manufacturing capabilities.
- Cellular Biomedicine Group
- Iovnace Biotherapeutics
- Lytix Biopharma
- Phio Pharmaceuticals
For additional details, please visit
https://www.rootsanalysis.com/reports/til-therapies-market.html or email email@example.com
You may also be interested in the following titles:
- Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030
- CAR-T Cell Therapies Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
- TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
- Cell and Gene Therapy CROs Market: Industry Trends and Global Forecasts (2nd Edition), 2021-2030
- Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at firstname.lastname@example.org
+1 (415) 800 3415